These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29126757)

  • 1. Quantifying the Rate of Ellipsoid Zone Loss in Stargardt Disease.
    Cai CX; Light JG; Handa JT
    Am J Ophthalmol; 2018 Feb; 186():1-9. PubMed ID: 29126757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodal analysis of the Preferred Retinal Location and the Transition Zone in patients with Stargardt Disease.
    Verdina T; Greenstein VC; Sodi A; Tsang SH; Burke TR; Passerini I; Allikmets R; Virgili G; Cavallini GM; Rizzo S
    Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1307-1317. PubMed ID: 28365912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of stargardt disease using polarization-sensitive optical coherence tomography and fundus autofluorescence imaging.
    Ritter M; Zotter S; Schmidt WM; Bittner RE; Deak GG; Pircher M; Sacu S; Hitzenberger CK; Schmidt-Erfurth UM;
    Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6416-25. PubMed ID: 23882696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease.
    Melillo P; Testa F; Rossi S; Di Iorio V; Orrico A; Auricchio A; Simonelli F
    Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT247-52. PubMed ID: 27409479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STARGARDT DISEASE: Beyond Flecks and Atrophy.
    Light JG; Fard MA; Yaseri M; Aiyetan P; Handa JT; Ebrahimi KB
    Retina; 2017 Dec; 37(12):2352-2361. PubMed ID: 28099317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of segmentation density on spectral domain optical coherence tomography assessment in Stargardt disease.
    Velaga SB; Nittala MG; Jenkins D; Melendez J; Ho A; Strauss RW; Scholl HP; Sadda SR
    Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):549-556. PubMed ID: 30613916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2.
    Pauleikhoff D; Bonelli R; Dubis AM; Gunnemann F; Rothaus K; Charbel Issa P; Heeren TF; Peto T; Clemons TE; Chew EY; Bird AC; Sallo FB;
    Acta Ophthalmol; 2019 Nov; 97(7):e998-e1005. PubMed ID: 30968592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement and Reproducibility of Preserved Ellipsoid Zone Area and Preserved Retinal Pigment Epithelium Area in Eyes With Choroideremia.
    Hariri AH; Velaga SB; Girach A; Ip MS; Le PV; Lam BL; Fischer MD; Sankila EM; Pennesi ME; Holz FG; MacLaren RE; Birch DG; Hoyng CB; MacDonald IM; Black GC; Tsang SH; Bressler NM; Larsen M; Gorin MB; Webster AR; Sadda SR;
    Am J Ophthalmol; 2017 Jul; 179():110-117. PubMed ID: 28499705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ULTRAWIDEFIELD AUTOFLUORESENCE IN ABCA4 STARGARDT DISEASE.
    Klufas MA; Tsui I; Sadda SR; Hosseini H; Schwartz SD
    Retina; 2018 Feb; 38(2):403-415. PubMed ID: 28248825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).
    Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Cideciyan AV; Audo I; Birch DG; Hariri AH; Nittala MG; Sadda S; West S; Scholl HPN;
    JAMA Ophthalmol; 2017 Nov; 135(11):1232-1241. PubMed ID: 29049437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early deterioration in ellipsoid zone in eyes with non-neovascular age-related macular degeneration.
    Toprak I; Yaylalı V; Yildirim C
    Int Ophthalmol; 2017 Aug; 37(4):801-806. PubMed ID: 27591785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Near-infrared autofluorescence: its relationship to short-wavelength autofluorescence and optical coherence tomography in recessive stargardt disease.
    Greenstein VC; Schuman AD; Lee W; Duncker T; Zernant J; Allikmets R; Hood DC; Sparrow JR
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3226-34. PubMed ID: 26024107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Contribution of multimodal imaging in the various stages of Stargardt disease].
    El Matri L; Falfoul Y; Kortli M; Hassairi A; Charfi H; Turki A; Kort F; Chebil A
    J Fr Ophtalmol; 2017 Oct; 40(8):666-675. PubMed ID: 28919188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with acute welding arc maculopathy.
    Zhang C; Dang G; Zhao T; Wang D; Su Y; Qu Y
    Int Ophthalmol; 2019 May; 39(5):1081-1088. PubMed ID: 29651692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Disease Progression in Atrophic Age-Related Macular Degeneration and Late-Onset Stargardt Disease.
    Lindner M; Lambertus S; Mauschitz MM; Bax NM; Kersten E; Lüning A; Nadal J; Schmitz-Valckenberg S; Schmid M; Holz FG; Hoyng CB; Fleckenstein M;
    Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):1001-1007. PubMed ID: 28288486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic comparison of spectral-domain optical coherence tomography and fundus autofluorescence in patients with geographic atrophy.
    Sayegh RG; Simader C; Scheschy U; Montuoro A; Kiss C; Sacu S; Kreil DP; Prünte C; Schmidt-Erfurth U
    Ophthalmology; 2011 Sep; 118(9):1844-51. PubMed ID: 21496928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELLIPSOID ZONE MAPPING AND OUTER RETINAL ASSESSMENT IN STARGARDT DISEASE.
    Arepalli S; Traboulsi EI; Ehlers JP
    Retina; 2018 Jul; 38(7):1427-1431. PubMed ID: 28613213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dark atrophy with indocyanine green angiography in Stargardt disease.
    Giani A; Pellegrini M; Carini E; Peroglio Deiro A; Bottoni F; Staurenghi G
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3999-4004. PubMed ID: 22589445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. En face OCT in Stargardt disease.
    Sodi A; Mucciolo DP; Cipollini F; Murro V; Caporossi O; Virgili G; Rizzo S
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1669-79. PubMed ID: 26743751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence Lifetime Imaging in Stargardt Disease: Potential Marker for Disease Progression.
    Dysli C; Wolf S; Hatz K; Zinkernagel MS
    Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):832-41. PubMed ID: 26934141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.